Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 311

1.

Tuberculous meningitis in children is characterized by compartmentalized immune responses and neural excitotoxicity.

Rohlwink UK, Figaji A, Wilkinson KA, Horswell S, Sesay AK, Deffur A, Enslin N, Solomons R, Van Toorn R, Eley B, Levin M, Wilkinson RJ, Lai RPJ.

Nat Commun. 2019 Aug 21;10(1):3767. doi: 10.1038/s41467-019-11783-9.

2.

Tuberculosis antigen-specific T cell responses during the first 6 months of antiretroviral treatment.

Riou C, Jhilmeet N, Rangaka MX, Wilkinson RJ, Wilkinson KA.

J Infect Dis. 2019 Aug 17. pii: jiz417. doi: 10.1093/infdis/jiz417. [Epub ahead of print]

3.

Key considerations in the pharmacotherapy of tuberculous meningitis.

Wasserman S, Davis A, Wilkinson RJ, Meintjes G.

Expert Opin Pharmacother. 2019 Jul 15:1-5. doi: 10.1080/14656566.2019.1638912. [Epub ahead of print] No abstract available.

PMID:
31305179
4.

Clinical, microbiologic, and immunologic determinants of mortality in hospitalized patients with HIV-associated tuberculosis: A prospective cohort study.

Schutz C, Barr D, Andrade BB, Shey M, Ward A, Janssen S, Burton R, Wilkinson KA, Sossen B, Fukutani KF, Nicol M, Maartens G, Wilkinson RJ, Meintjes G.

PLoS Med. 2019 Jul 5;16(7):e1002840. doi: 10.1371/journal.pmed.1002840. eCollection 2019 Jul.

5.

Invariant Natural Killer T cell dynamics in HIV-associated tuberculosis.

Walker NF, Opondo C, Meintjes G, Jhilmeet N, Friedland JS, Elkington PT, Wilkinson RJ, Wilkinson KA.

Clin Infect Dis. 2019 Jun 12. pii: ciz501. doi: 10.1093/cid/ciz501. [Epub ahead of print]

6.

Matrix Metalloproteinases in Pulmonary and Central Nervous System Tuberculosis-A Review.

Rohlwink UK, Walker NF, Ordonez AA, Li YJ, Tucker EW, Elkington PT, Wilkinson RJ, Wilkinson KA.

Int J Mol Sci. 2019 Mar 18;20(6). pii: E1350. doi: 10.3390/ijms20061350. Review.

7.

Effects of an unprecedented summer heatwave on the growth performance, flesh colour and plasma biochemistry of marine cage-farmed Atlantic salmon (Salmo salar).

Wade NM, Clark TD, Maynard BT, Atherton S, Wilkinson RJ, Smullen RP, Taylor RS.

J Therm Biol. 2019 Feb;80:64-74. doi: 10.1016/j.jtherbio.2018.12.021. Epub 2018 Dec 27.

PMID:
30784489
8.

Elevated Matrix Metalloproteinase Concentrations Offer Novel Insight Into Their Role in Pediatric Tuberculous Meningitis.

Li YJ, Wilkinson KA, Wilkinson RJ, Figaji AA, Rohlwink UK.

J Pediatric Infect Dis Soc. 2019 Feb 12. doi: 10.1093/jpids/piy141. [Epub ahead of print]

9.

Drug susceptibility testing and mortality in patients treated for tuberculosis in high-burden countries: a multicentre cohort study.

Zürcher K, Ballif M, Fenner L, Borrell S, Keller PM, Gnokoro J, Marcy O, Yotebieng M, Diero L, Carter EJ, Rockwood N, Wilkinson RJ, Cox H, Ezati N, Abimiku AG, Collantes J, Avihingsanon A, Kawkitinarong K, Reinhard M, Hömke R, Huebner R, Gagneux S, Böttger EC, Egger M; International epidemiology Databases to Evaluate AIDS (IeDEA) consortium.

Lancet Infect Dis. 2019 Mar;19(3):298-307. doi: 10.1016/S1473-3099(18)30673-X. Epub 2019 Feb 8.

10.

The pathogenesis of tuberculous meningitis.

Davis AG, Rohlwink UK, Proust A, Figaji AA, Wilkinson RJ.

J Leukoc Biol. 2019 Feb;105(2):267-280. doi: 10.1002/JLB.MR0318-102R. Epub 2019 Jan 15. Review.

PMID:
30645042
11.

The effect of antiretroviral treatment on selected genes in whole blood from HIV-infected adults sensitised by Mycobacterium tuberculosis.

Jhilmeet N, Lowe DM, Riou C, Scriba TJ, Coussens A, Goliath R, Wilkinson RJ, Wilkinson KA.

PLoS One. 2018 Dec 27;13(12):e0209516. doi: 10.1371/journal.pone.0209516. eCollection 2018.

12.

Neutrophils: Innate Effectors of TB Resistance?

Kroon EE, Coussens AK, Kinnear C, Orlova M, Möller M, Seeger A, Wilkinson RJ, Hoal EG, Schurr E.

Front Immunol. 2018 Nov 14;9:2637. doi: 10.3389/fimmu.2018.02637. eCollection 2018. Review.

13.

ANIMA: Association network integration for multiscale analysis.

Deffur A, Wilkinson RJ, Mayosi BM, Mulder NM.

Version 2. Wellcome Open Res. 2018 Nov 14 [revised 2018 Jan 1];3:27. doi: 10.12688/wellcomeopenres.14073.3. eCollection 2018.

14.

Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS.

Meintjes G, Stek C, Blumenthal L, Thienemann F, Schutz C, Buyze J, Ravinetto R, van Loen H, Nair A, Jackson A, Colebunders R, Maartens G, Wilkinson RJ, Lynen L; PredART Trial Team.

N Engl J Med. 2018 Nov 15;379(20):1915-1925. doi: 10.1056/NEJMoa1800762.

15.

The Immune Mechanisms of Lung Parenchymal Damage in Tuberculosis and the Role of Host-Directed Therapy.

Stek C, Allwood B, Walker NF, Wilkinson RJ, Lynen L, Meintjes G.

Front Microbiol. 2018 Oct 30;9:2603. doi: 10.3389/fmicb.2018.02603. eCollection 2018. Review.

16.

A Systematic Review on the Effect of HIV Infection on the Pharmacokinetics of First-Line Tuberculosis Drugs.

Daskapan A, Idrus LR, Postma MJ, Wilffert B, Kosterink JGW, Stienstra Y, Touw DJ, Andersen AB, Bekker A, Denti P, Hemanth Kumar AK, Jeremiah K, Kwara A, McIlleron H, Meintjes G, van Oosterhout JJ, Ramachandran G, Rockwood N, Wilkinson RJ, van der Werf TS, Alffenaar JC.

Clin Pharmacokinet. 2019 Jun;58(6):747-766. doi: 10.1007/s40262-018-0716-8. Review.

17.

The value of transcriptomics in advancing knowledge of the immune response and diagnosis in tuberculosis.

Singhania A, Wilkinson RJ, Rodrigue M, Haldar P, O'Garra A.

Nat Immunol. 2018 Nov;19(11):1159-1168. doi: 10.1038/s41590-018-0225-9. Epub 2018 Oct 17. Review.

18.

Projected population-wide impact of antiretroviral therapy-linked isoniazid preventive therapy in a high-burden setting.

Kendall EA, Azman AS, Maartens G, Boulle A, Wilkinson RJ, Dowdy DW, Rangaka MX.

AIDS. 2019 Mar 1;33(3):525-536. doi: 10.1097/QAD.0000000000002053.

PMID:
30325773
19.

Recent progress in understanding immune activation in the pathogenesis in HIV-tuberculosis co-infection.

du Bruyn E, Peton N, Esmail H, Howlett PJ, Coussens AK, Wilkinson RJ.

Curr Opin HIV AIDS. 2018 Nov;13(6):455-461. doi: 10.1097/COH.0000000000000501. Review.

PMID:
30286038
20.

Phase 2b Controlled Trial of M72/AS01E Vaccine to Prevent Tuberculosis.

Van Der Meeren O, Hatherill M, Nduba V, Wilkinson RJ, Muyoyeta M, Van Brakel E, Ayles HM, Henostroza G, Thienemann F, Scriba TJ, Diacon A, Blatner GL, Demoitié MA, Tameris M, Malahleha M, Innes JC, Hellström E, Martinson N, Singh T, Akite EJ, Khatoon Azam A, Bollaerts A, Ginsberg AM, Evans TG, Gillard P, Tait DR.

N Engl J Med. 2018 Oct 25;379(17):1621-1634. doi: 10.1056/NEJMoa1803484. Epub 2018 Sep 25.

21.

Plasma Biomarkers to Detect Prevalent or Predict Progressive Tuberculosis Associated With Human Immunodeficiency Virus-1.

Lesosky M, Rangaka MX, Pienaar C, Coussens AK, Goliath R, Mathee S, Mwansa-Kambafwile J, Maartens G, Wilkinson RJ, Wilkinson KA.

Clin Infect Dis. 2019 Jul 2;69(2):295-305. doi: 10.1093/cid/ciy823.

22.

PD-1 Expression on Mycobacterium tuberculosis-Specific CD4 T Cells Is Associated With Bacterial Load in Human Tuberculosis.

Day CL, Abrahams DA, Bunjun R, Stone L, de Kock M, Walzl G, Wilkinson RJ, Burgers WA, Hanekom WA.

Front Immunol. 2018 Aug 31;9:1995. doi: 10.3389/fimmu.2018.01995. eCollection 2018.

23.

Improving the microbiological diagnosis of tuberculous meningitis: A prospective, international, multicentre comparison of conventional and modified Ziehl-Neelsen stain, GeneXpert, and culture of cerebrospinal fluid.

Heemskerk AD, Donovan J, Thu DDA, Marais S, Chaidir L, Dung VTM, Centner CM, Ha VTN, Annisa J, Dian S, Bovijn L, Mai NTH, Phu NH, Chau NVV, Ganiem AR, Van CT, Geskus RB, Thuong NTT, Ruslami R, Meintjes G, van Crevel R, Wilkinson RJ, Thwaites GE.

J Infect. 2018 Dec;77(6):509-515. doi: 10.1016/j.jinf.2018.09.003. Epub 2018 Sep 12.

24.

Host resistance to pulmonary Mycobacterium tuberculosis infection requires CD153 expression.

Sallin MA, Kauffman KD, Riou C, Du Bruyn E, Foreman TW, Sakai S, Hoft SG, Myers TG, Gardina PJ, Sher A, Moore R, Wilder-Kofie T, Moore IN, Sette A, Lindestam Arlehamn CS, Wilkinson RJ, Barber DL.

Nat Microbiol. 2018 Nov;3(11):1198-1205. doi: 10.1038/s41564-018-0231-6. Epub 2018 Sep 10.

25.

Corticosteroids as an adjunct to tuberculosis therapy.

Schutz C, Davis AG, Sossen B, Lai RP, Ntsekhe M, Harley YX, Wilkinson RJ.

Expert Rev Respir Med. 2018 Oct;12(10):881-891. doi: 10.1080/17476348.2018.1515628. Epub 2018 Sep 6. Review.

26.

The tuberculosis-associated immune reconstitution inflammatory syndrome: recent advances in clinical and pathogenesis research.

Walker NF, Stek C, Wasserman S, Wilkinson RJ, Meintjes G.

Curr Opin HIV AIDS. 2018 Nov;13(6):512-521. doi: 10.1097/COH.0000000000000502.

27.

A semi-automatic technique to quantify complex tuberculous lung lesions on 18F-fluorodeoxyglucose positron emission tomography/computerised tomography images.

Malherbe ST, Dupont P, Kant I, Ahlers P, Kriel M, Loxton AG, Chen RY, Via LE, Thienemann F, Wilkinson RJ, Barry CE 3rd, Griffith-Richards S, Ellman A, Ronacher K, Winter J, Walzl G, Warwick JM; Catalysis Biomarker Consortium.

EJNMMI Res. 2018 Jun 25;8(1):55. doi: 10.1186/s13550-018-0411-7.

28.

A modular transcriptional signature identifies phenotypic heterogeneity of human tuberculosis infection.

Singhania A, Verma R, Graham CM, Lee J, Tran T, Richardson M, Lecine P, Leissner P, Berry MPR, Wilkinson RJ, Kaiser K, Rodrigue M, Woltmann G, Haldar P, O'Garra A.

Nat Commun. 2018 Jun 19;9(1):2308. doi: 10.1038/s41467-018-04579-w.

29.

Differential Effect of Viable Versus Necrotic Neutrophils on Mycobacterium tuberculosis Growth and Cytokine Induction in Whole Blood.

Lowe DM, Demaret J, Bangani N, Nakiwala JK, Goliath R, Wilkinson KA, Wilkinson RJ, Martineau AR.

Front Immunol. 2018 Apr 27;9:903. doi: 10.3389/fimmu.2018.00903. eCollection 2018.

30.

Effect of prednisolone on inflammatory markers in pericardial tuberculosis: A pilot study.

Shenje J, Lai RP, Ross IL, Mayosi BM, Wilkinson RJ, Ntsekhe M, Wilkinson KA.

Int J Cardiol Heart Vasc. 2017 Nov 3;18:104-108. doi: 10.1016/j.ijcha.2017.10.002. eCollection 2018 Mar.

31.

Using biomarkers to predict TB treatment duration (Predict TB): a prospective, randomized, noninferiority, treatment shortening clinical trial.

Chen RY, Via LE, Dodd LE, Walzl G, Malherbe ST, Loxton AG, Dawson R, Wilkinson RJ, Thienemann F, Tameris M, Hatherill M, Diacon AH, Liu X, Xing J, Jin X, Ma Z, Pan S, Zhang G, Gao Q, Jiang Q, Zhu H, Liang L, Duan H, Song T, Alland D, Tartakovsky M, Rosenthal A, Whalen C, Duvenhage M, Cai Y, Goldfeder LC, Arora K, Smith B, Winter J, Barry Iii CE; Predict TB Study Group.

Gates Open Res. 2017 Nov 6;1:9. doi: 10.12688/gatesopenres.12750.1.

32.

Treatment of Tuberculous Meningitis and Its Complications in Adults.

Davis A, Meintjes G, Wilkinson RJ.

Curr Treat Options Neurol. 2018 Feb 28;20(3):5. doi: 10.1007/s11940-018-0490-9. Review.

33.

The Immune Response to Mycobacterium tuberculosis in HIV-1-Coinfected Persons.

Esmail H, Riou C, Bruyn ED, Lai RP, Harley YXR, Meintjes G, Wilkinson KA, Wilkinson RJ.

Annu Rev Immunol. 2018 Apr 26;36:603-638. doi: 10.1146/annurev-immunol-042617-053420. Epub 2018 Feb 28. Review.

PMID:
29490165
34.

UK's role in global health research innovation.

Mannell J, Abubakar I, Bastawrous A, Osrin D, Patel P, Piot P, Prince M, Smith J, Wilkinson RJ, Horton R.

Lancet. 2018 Feb 24;391(10122):721-723. doi: 10.1016/S0140-6736(18)30303-9. No abstract available.

35.

HIV-Associated Mycobacterium tuberculosis Bloodstream Infection Is Underdiagnosed by Single Blood Culture.

Barr DA, Kerkhoff AD, Schutz C, Ward AM, Davies GR, Wilkinson RJ, Meintjes G.

J Clin Microbiol. 2018 Apr 25;56(5). pii: e01914-17. doi: 10.1128/JCM.01914-17. Print 2018 May.

36.

The prevalence and determinants of active tuberculosis among diabetes patients in Cape Town, South Africa, a high HIV/TB burden setting.

Berkowitz N, Okorie A, Goliath R, Levitt N, Wilkinson RJ, Oni T.

Diabetes Res Clin Pract. 2018 Apr;138:16-25. doi: 10.1016/j.diabres.2018.01.018. Epub 2018 Jan 31.

37.

Aiming at the Global Elimination of Viral Hepatitis: Challenges Along the Care Continuum.

Heffernan A, Barber E, Cook NA, Gomaa AI, Harley YX, Jones CR, Lim AG, Mohamed Z, Nayagam S, Ndow G, Shah R, Sonderup MW, Spearman CW, Waked I, Wilkinson RJ, Taylor-Robinson SD.

Open Forum Infect Dis. 2017 Nov 17;5(1):ofx252. doi: 10.1093/ofid/ofx252. eCollection 2018 Jan.

38.

Complement pathway gene activation and rising circulating immune complexes characterize early disease in HIV-associated tuberculosis.

Esmail H, Lai RP, Lesosky M, Wilkinson KA, Graham CM, Horswell S, Coussens AK, Barry CE 3rd, O'Garra A, Wilkinson RJ.

Proc Natl Acad Sci U S A. 2018 Jan 30;115(5):E964-E973. doi: 10.1073/pnas.1711853115. Epub 2018 Jan 16.

39.

Neutrophil Activation and Enhanced Release of Granule Products in HIV-TB Immune Reconstitution Inflammatory Syndrome.

Nakiwala JK, Walker NF, Diedrich CR, Worodria W, Meintjes G, Wilkinson RJ, Mayanja-Kizza H, Colebunders R, Kestens L, Wilkinson KA, Lowe DM.

J Acquir Immune Defic Syndr. 2018 Feb 1;77(2):221-229. doi: 10.1097/QAI.0000000000001582. Erratum in: J Acquir Immune Defic Syndr. 2018 Jun 1;78(2):e13.

40.

Effect of HIV on the Frequency and Number of Mycobacterium tuberculosis-Specific CD4+ T Cells in Blood and Airways During Latent M. tuberculosis Infection.

Bunjun R, Riou C, Soares AP, Thawer N, Müller TL, Kiravu A, Ginbot Z, Oni T, Goliath R, Kalsdorf B, von Groote-Bidlingmaier F, Hanekom W, Walzl G, Wilkinson RJ, Burgers WA.

J Infect Dis. 2017 Dec 19;216(12):1550-1560. doi: 10.1093/infdis/jix529.

41.

Low Frequency of Acquired Isoniazid and Rifampicin Resistance in Rifampicin-Susceptible Pulmonary Tuberculosis in a Setting of High HIV-1 Infection and Tuberculosis Coprevalence.

Rockwood N, Sirgel F, Streicher E, Warren R, Meintjes G, Wilkinson RJ.

J Infect Dis. 2017 Sep 15;216(6):632-640. doi: 10.1093/infdis/jix337.

42.

Tuberculous meningitis.

Wilkinson RJ, Rohlwink U, Misra UK, van Crevel R, Mai NTH, Dooley KE, Caws M, Figaji A, Savic R, Solomons R, Thwaites GE; Tuberculous Meningitis International Research Consortium.

Nat Rev Neurol. 2017 Oct;13(10):581-598. doi: 10.1038/nrneurol.2017.120. Epub 2017 Sep 8. Review.

PMID:
28884751
43.

Analysis of the Phenotype of Mycobacterium tuberculosis-Specific CD4+ T Cells to Discriminate Latent from Active Tuberculosis in HIV-Uninfected and HIV-Infected Individuals.

Riou C, Berkowitz N, Goliath R, Burgers WA, Wilkinson RJ.

Front Immunol. 2017 Aug 10;8:968. doi: 10.3389/fimmu.2017.00968. eCollection 2017.

44.

Characterization of Mycobacterium tuberculosis-Specific Cells Using MHC Class II Tetramers Reveals Phenotypic Differences Related to HIV Infection and Tuberculosis Disease.

Strickland N, Müller TL, Berkowitz N, Goliath R, Carrington MN, Wilkinson RJ, Burgers WA, Riou C.

J Immunol. 2017 Aug 9. pii: ji1700849. doi: 10.4049/jimmunol.1700849. [Epub ahead of print]

45.

Trilateral overlap of tuberculosis, diabetes and HIV-1 in a high-burden African setting: implications for TB control.

Oni T, Berkowitz N, Kubjane M, Goliath R, Levitt NS, Wilkinson RJ.

Eur Respir J. 2017 Jul 20;50(1). pii: 1700004. doi: 10.1183/13993003.00004-2017. Print 2017 Jul.

46.

Biomarkers of Cerebral Injury and Inflammation in Pediatric Tuberculous Meningitis.

Rohlwink UK, Mauff K, Wilkinson KA, Enslin N, Wegoye E, Wilkinson RJ, Figaji AA.

Clin Infect Dis. 2017 Oct 15;65(8):1298-1307. doi: 10.1093/cid/cix540.

47.

Mycobacterium tuberculosis Induction of Heme Oxygenase-1 Expression Is Dependent on Oxidative Stress and Reflects Treatment Outcomes.

Rockwood N, Costa DL, Amaral EP, Du Bruyn E, Kubler A, Gil-Santana L, Fukutani KF, Scanga CA, Flynn JL, Jackson SH, Wilkinson KA, Bishai WR, Sher A, Wilkinson RJ, Andrade BB.

Front Immunol. 2017 May 12;8:542. doi: 10.3389/fimmu.2017.00542. eCollection 2017.

48.

A Rab20-Dependent Membrane Trafficking Pathway Controls M. tuberculosis Replication by Regulating Phagosome Spaciousness and Integrity.

Schnettger L, Rodgers A, Repnik U, Lai RP, Pei G, Verdoes M, Wilkinson RJ, Young DB, Gutierrez MG.

Cell Host Microbe. 2017 May 10;21(5):619-628.e5. doi: 10.1016/j.chom.2017.04.004.

49.

Matrix Degradation in Human Immunodeficiency Virus Type 1-Associated Tuberculosis and Tuberculosis Immune Reconstitution Inflammatory Syndrome: A Prospective Observational Study.

Walker NF, Wilkinson KA, Meintjes G, Tezera LB, Goliath R, Peyper JM, Tadokera R, Opondo C, Coussens AK, Wilkinson RJ, Friedland JS, Elkington PT.

Clin Infect Dis. 2017 Jul 1;65(1):121-132. doi: 10.1093/cid/cix231.

50.

Minimizing Tuberculosis Risk in Patients Receiving Anti-TNF Therapy.

Esmail H, Wilkinson RJ.

Ann Am Thorac Soc. 2017 May;14(5):621-623. doi: 10.1513/AnnalsATS.201701-055ED. No abstract available.

Supplemental Content

Loading ...
Support Center